GLP-1: How Weight-Loss Drugs Are Rewriting Diagnostics Demand

Picture a Tuesday morning at a private clinic in Monterrey. A 47-year-old executive walks in, phone in hand, asking about “the injection everyone is talking about.” The physician decides the treatment may be appropriate. What happens next is less photogenic: baseline blood work, a follow-up plan, and a series of measurements that will determine whether the therapy is actually improving health.

Everyone sees the pen. Nobody sees the panel.

Yet that panel may be one of the most important business stories created by the GLP-1 boom.

The Pill Changed the Size of the Wave

For the past two years, the GLP-1 conversation has revolved around shortages, pricing, and injections. That framing is already changing. Oral semaglutide for weight management entered the US market in early 2026, while Eli Lilly’s once-daily oral GLP-1 orforglipron has pushed the category further toward mass-market convenience.

In ATTAIN-1, more than 3,100 adults with obesity or overweight and a weight-related condition were studied for 72 weeks; participants receiving the highest dose of orforglipron achieved mean weight loss of 12.4% using the efficacy estimand. In ACHIEVE-3, published in The Lancet, orforglipron also produced greater reductions in HbA1c and weight than the oral semaglutide doses used in the trial.

Why does a pill matter so much? Because pills scale differently. They are easier to distribute, easier for primary care to incorporate, and easier for patients to accept. As access expands, the center of gravity of GLP-1 treatment can move beyond specialist offices.

Diagnostics will have to move with it.

Mexico Is the Natural Market

The numbers are hard to ignore. ENSANUT 2022 estimated obesity prevalence among Mexican adults at 36.9% and overweight at 38.3%. The same survey estimated total diabetes prevalence at 18.3%, with another 22.1% of adults living with prediabetes.

Taken together, overweight and obesity affect roughly 3 out of every 4 Mexican adults. That does not mean 3 out of 4 adults are candidates for GLP-1 therapy; indication depends on BMI, comorbidities, and clinical judgment. But it does tell us something important about scale: Mexico has an enormous cardiometabolic population that could increasingly intersect with this drug class.

Read those numbers as a laboratory executive would. This is not simply a market of affluent patients pursuing weight loss. It is a much larger shift in the way obesity, diabetes, and cardiovascular risk are identified, treated, and followed.

What a Prescription Really Creates

A GLP-1 prescription can also create a laboratory journey.

The exact testing depends on the patient and the indication, but contemporary obesity care commonly includes measures such as HbA1c, a lipid profile, liver enzymes, creatinine, and estimated kidney function. Thyroid or nutritional testing may be appropriate when the clinical picture calls for it. And the 2026 American Diabetes Association obesity standards explicitly emphasize regular follow-up and monitoring of relevant laboratory values over time.

Once treatment begins, the questions become measurable. Is glycemic control improving? Are triglycerides changing? Is kidney function stable? What is happening to the patient’s broader cardiometabolic risk profile?

That is why I think the diagnostics industry should resist treating these assays as mature, flat-volume commodities. GLP-1 adoption may create new testing frequency, new patient pathways, and new opportunities to package monitoring around a treatment journey rather than around isolated analytes.

The lipid story alone is becoming more sophisticated. The 2026 ACC/AHA dyslipidemia guideline gives a larger role to selective apolipoprotein B testing, particularly in people with diabetes, high triglycerides, or cardiometabolic risk in whom LDL cholesterol may not tell the whole story. That does not mean ApoB suddenly replaces the standard lipid panel. It means the laboratory’s role in cardiometabolic risk assessment is expanding at the same time the therapeutic toolkit is expanding.

The Two-Speed Risk

This is where the opportunity becomes a concern.

Private access can move very quickly: self-pay patients, telehealth, pharmacy channels, and increasingly convenient formulations. Structured monitoring pathways do not always move at the same speed. Public systems face a different challenge: deciding how new therapies fit into formularies, clinical pathways, and already-stretched diagnostic capacity.

The risk is not the drug itself. The risk is separating access to treatment from longitudinal care.

Without proper monitoring, a powerful cardiometabolic therapy can start being treated like a cosmetic product. With proper monitoring, it becomes what it is supposed to be: a medical intervention whose outcomes can be measured, adjusted, and managed.

Imagine 1 million additional Mexican patients eventually using this class of therapy. Even if only a fraction require additional laboratory testing at regular intervals, the volume implications become material. And if the monitoring does not happen, the clinical risk does not disappear. It simply moves somewhere else in the healthcare system.

What Should the Industry Do?

For laboratory chains, build the pathway. A “GLP-1 start” profile and a “GLP-1 follow-up” profile may be more useful to patients and physicians than asking them to assemble individual tests one by one. The laboratory should be present where treatment decisions happen, not as an afterthought several steps later.

For IVD manufacturers — my own industry included — rebuild the forecast. HbA1c, lipids, renal and hepatic chemistry should not automatically be modeled against last year’s run rate. Scenario-plan demand against GLP-1 penetration, patient persistence, and new monitoring protocols. Instrument capacity and reagent availability need to be ahead of the curve.

For insurers and employers, drug cost and monitoring cost should be viewed as one clinical pathway. Funding the therapy while ignoring the measurements needed to evaluate it is a false economy.

And for regulators, medical societies, pharmacies, and providers, the opportunity is to make simple monitoring standards easier to follow as access expands — not to create another barrier to treatment, but to make broad access safer and more accountable.

The Number Nobody Is Tracking

Mexico is spending plenty of energy debating whether patients, insurers, and health systems can afford GLP-1 therapies. That is a legitimate question.

But there is another one: Can we afford to scale the drug faster than we scale the diagnostics around it?

The GLP-1 revolution will not be measured only in prescriptions written or kilograms lost. It will also be measured in HbA1c values, lipid profiles, renal function, risk reduction, and years of follow-up.

The pen is the headline.

The panel is the outcome.

Which one is your organization building for?